FDA Docs Cast Doubt On Capricor's Deramiocel Approval

FDA released documents ahead of an advisory committee meeting on Capricor's Deramiocel application.

Documents paint an 'ugly picture' according to some analysts.

Wall Street experts are divided on Deramiocel's approval probability.

Capricor's stock (CAPR) is on track for its worst day ever.